Vincent D. Enright
About Vincent D. Enright
Independent Trustee of The Gabelli Global Utility & Income Trust (GLU) since 2004; year of birth: 1943. Former Senior Vice President and Chief Financial Officer of KeySpan Corp. (public utility) and designated GLU Audit Committee Financial Expert; education includes a Bachelor’s degree from Fordham University and completion of Harvard University’s Advanced Management Program .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| KeySpan Corp. (public utility) | Senior Vice President & Chief Financial Officer | 1994–1998 | Senior executive oversight of finance at a public utility |
| Therapeutics & diagnostics company (Echo Therapeutics, Inc.) | Director | 2008–2014 | Chairman of Compensation Committee; member of Audit Committee |
| Diversified manufacturing company (The LGL Group, Inc.) | Director | 2011–2014 | Board oversight; industry/diversified manufacturing exposure |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Echo Therapeutics, Inc. | Director | 2008–2014 | Chaired Compensation; served on Audit |
| The LGL Group, Inc. | Director | 2011–2014 | Director |
Board Governance
- Committee assignments: Chairman, Audit Committee; Chairman, Nominating Committee; member, ad hoc Proxy Voting Committee; member of both multi‑fund ad hoc Compensation Committees; GLU Audit Committee Financial Expert designation .
- Independence status: GLU’s Board consists entirely of “Independent” Trustees not considered “interested persons” under the 1940 Act .
- Attendance and engagement: In FY2024, Board met 4 times; each Trustee attended at least 75% of Board and applicable committee meetings; Audit Committee met twice; Nominating Committee met twice. In FY2023, Board met 4 times; each Trustee attended at least 75%; Audit Committee met twice; Nominating Committee met once .
- Lead Independent Director: James P. Conn; independent Trustees meet regularly in executive session; committees chaired by Independent Trustees .
- Shareholder meeting attendance: GLU does not expect Trustees/nominees to attend the meeting; none attended the annual meeting held May 13, 2024 .
| Governance Metric | FY 2023 | FY 2024 |
|---|---|---|
| Board meetings held | 4 | 4 |
| Audit Committee meetings | 2 | 2 |
| Nominating Committee meetings | 1 | 2 |
| Trustee attendance (Board and committees) | ≥75% for each Trustee | ≥75% for each Trustee |
| Lead Independent Director | James P. Conn | James P. Conn |
Fixed Compensation
| Component | Amount/Structure | Source |
|---|---|---|
| Annual retainer (Independent Trustee) | $3,000 | |
| Board meeting fee | $1,000 per meeting | |
| Committee meeting fee | $500 per meeting | |
| Audit Committee Chair fee | $3,000 annually | |
| Nominating Committee Chair fee | $2,000 annually | |
| Lead Independent Trustee fee | $1,000 annually (note: Enright is not LID) | |
| Single meeting fee across multiple funds (if applicable) | Allowed (allocated among participating funds) |
| Individual Compensation (GLU only) | FY 2023 | FY 2024 |
|---|---|---|
| Aggregate compensation from GLU (Vincent D. Enright) | $13,500 | $13,000 |
| Aggregate compensation from Fund Complex (total across funds) | $218,263 (17 funds) | $217,637 (17 funds) |
Performance Compensation
| Metric | Disclosure |
|---|---|
| Equity awards to Trustees (RSUs/PSUs/Options) | Not disclosed for Trustees in GLU proxy materials; compensation shown for Trustees is cash retainers/meeting/committee fees |
| Performance metrics tied to Trustee pay | None disclosed for Trustees |
| Clawbacks, severance, CIC provisions for Trustees | Not disclosed/applicable to Trustees |
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company boards | None disclosed for Enright in past five years (excluding other funds) |
| Past public company boards | Echo Therapeutics, Inc. (2008–2014); The LGL Group, Inc. (2011–2014) |
| Interests in adviser-affiliated entities (common control) | Enright not listed among Independent Trustees with such interests; table lists Conn, Melarkey, Zizza—not Enright |
| Potential interlocks with competitors/suppliers/customers | None disclosed for Enright |
Expertise & Qualifications
- Financial expertise: Designated Audit Committee Financial Expert; former CFO of KeySpan Corp.; prior service as compensation chair and audit committee member at Echo Therapeutics .
- Education: Bachelor’s degree (Fordham University); Advanced Management Program (Harvard University) .
- Sector exposure: Utilities (KeySpan), manufacturing (LGL Group), therapeutics/diagnostics (Echo) .
Equity Ownership
| Holder | Shares | Type | % of Shares Outstanding | Dollar Range (GLU) | Aggregate Dollar Range (Fund Complex) |
|---|---|---|---|---|---|
| Vincent D. Enright | 250 | Common | ≈0.0042% (250/5,978,272) | B ($1–$10,000) | E (Over $100,000) |
Notes: Beneficial ownership as reported December 31, 2024; Trustees/officers as a group hold <1% of Common and Preferred shares .
Insider Filings & Trades
| Item | Status |
|---|---|
| Section 16(a) filings compliance (FY2024) | Fund states such persons complied with filing requirements during FY2024 |
| Late filings noted | None for Enright; FY2023 late Form 4 noted for Melarkey (not Enright) |
| Form 4 trades for Enright (GLU) | Not disclosed in proxy materials; SEC Form 4 documents not present in GLU document catalog during review |
Governance Assessment
- Strengths: Independent trustee with deep finance credentials; chairs both Audit and Nominating Committees and is GLU’s Audit Committee Financial Expert—strong oversight signal; committee activity and regular executive sessions enhance board effectiveness .
- Alignment: Modest direct GLU ownership (250 shares; dollar range B) and no disclosed equity-based director awards—cash-only structure limits pay-for-performance linkage but reduces equity-related conflicts .
- Engagement: Attendance thresholds met; board/committee cadence consistent; GLU’s practice of trustees not attending shareholder meetings could be perceived as lower direct investor engagement, though disclosed as policy .
- Conflicts/Red Flags: No disclosed related-party interests involving Enright with adviser-affiliated entities; no Section 16(a) compliance issues noted for Enright; no pledging/hedging disclosed in proxy materials reviewed. Overall, low conflict profile for Enright .